Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1425-1434

  Tessier, Pamela R ^a   Kim, Myo Kyoung ^a   Zhou, Wen ^a   Xuan, Dawei ^a   Li, Chonghua ^a   Ye, Min ^a   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; MACROLIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOCOMPETENCE; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LUNG; MICE; MICE, INBRED CBA; MICE, INBRED ICR; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0036235528     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1425-1434.2002     Document Type: Article

References (25)

1. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations
2. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice
3. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens
4. Pharmacodynamics of macrolides, azalides, and streptogramins: Effect on extracellular pathogens
5. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo
6. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the Sentry antimicrobial surveillance program
7. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
8. Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance
9. Proposed institutional animal care and use committee guidelines for death as an end point in rodent studies
10. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem
11. Comparison of bacterial activity after multidose administration of clarithromycin, azithromycin, and cefuroxime axetil against Streptococcus pneumoniae
12. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia
13. Pharmacokinetics and pharmacodynamics of newer macrolides
14. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin
15. Clarithromycin: Pharmacokinetic and pharmacodynamic interrelationships and dosage regimen
16. Nomenclature for macrolide and macrolide-lincosamidestreptogramin B resistance determinants
17. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
18. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model
19. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
20. Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia
21. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infection caused by strains of Streptococcus pneumoniae
22. The newer macrolides: Azithromycin and clarithromycin